XenoPort Announces Initiation of a Phase 1 Clinical Trial of XP23829, a Novel Fumarate Analog for the Potential Treatment of Relapsing-Remitting Multiple Sclerosis and Psoriasis
XenoPort, Inc. (Nasdaq: XNPT) announced today that the first subjects have been dosed in a Phase 1, randomized, double-blind, two-period crossover, food effect comparison study of XP23829 in healthy adults. The trial is designed to assess the pharmacokinetics, safety and tolerability of a single dose of XP23829 administered in both fasted and fed conditions.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.